Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edwards Lifesciences

72.80
+1.421.98%
Volume:1.71M
Turnover:123.62M
Market Cap:42.80B
PE:10.45
High:72.91
Open:71.25
Low:70.95
Close:71.38
Loading ...

Company Profile

Company Name:
Edwards Lifesciences
Exchange:
NYSE
Establishment Date:
1958
Employees:
19800
Office Location:
One Edwards Way,Irvine,California,United States
Zip Code:
92614
Fax:
949 250 2525
Introduction:
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Directors

Name
Position
Bernard J. Zovighian
Director and Chief Executive Officer
Nicholas J. Valeriani
Chairman
David T. Feinberg
Director
Kieran T. Gallahue
Director
Leslie S. Heisz
Director
Paul. A. LaViolette
Director
Ramona Sequeira
Director
Steven R. Loranger
Director

Shareholders

Name
Position
Bernard J. Zovighian
Director and Chief Executive Officer
Andrew M. Dahl
Senior Vice President, Principal Accounting Officer
Scott B. Ullem
Corporate Vice President, Chief Financial Officer
Wayne Markowitz
General Manager and Senior Vice President, Surgical Structural Heart
Catherine M. Szyman
Corporate Vice President, Critical Care
Daniel Lippis
Corporate Vice President, JAPAC
Daveen Chopra
Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies
Donald E. Bobo, Jr.
Corporate Vice President, Strategy & Corporate Development
Jean Luc Lemercier
Corporate Vice President, EMEACLA
Larry L. Wood
Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart